Help Give Your Patients Breathing Relief They Can Feel
DUPIXENT is the only biologic that targets IL‑4 and IL‑13 signaling, two of the key drivers of local and systemic type 2 inflammation.1-5,a
aThe mechanism of dupilumab action has not been definitively established.1
Make DUPIXENT Your
First-Choice
Biologic
#1 Prescribed Biologic by
ALLERGISTS6,b
#1 Prescribed Biologic by
Pulmonologists for
Asthma
Patients7,c
Prescribed to >165,000 asthma patients by >20,000 healthcare providers in the United States8,d,e
b#1 prescribed biologic by allergists includes the aggregate number of new to brand across all indications. Source: Data on file, Sanofi US. New to Brand Monthly Audit; data through December 2024.
cIQVIA NSOB Monthly; data through June 30, 2024.
dLH Patient View; data through January 3, 2025.
eNew adult and pediatric patients aged 6 years and older with moderate-to-severe eosinophilic or OCS‑dependent asthma.1,8
DUPIXENT is the Only Biologic that Combines the Ability to:
Target
More Than One
Source of
Type 2 Inflammation by
Specifically Inhibiting
- IL-4 and IL-13 are two of the key drivers of local and systemic type 2 inflammation1-5,a
aThe mechanism of dupilumab action has not been definitively established.1
Explorethe MoA
Treat
More Than One
Asthma
Patient Type
- Specifically indicated for OCS-dependent asthma patients and for moderate-to-severe asthma patients with eosinophilic phenotype1
-
Markers of type 2 inflammation: proven data in indicated patients with ≥1 of the
following9,10
- EOS ≥150 cells/µL
- IgE ≥30 IU/mLe
- FeNO ≥20 ppb
PATIENT TYPES
Control
More Than One
Measure of
Uncontrolled Asthma
- Exacerbation reduction: Up to 81% significant reduction in annualized rate of severe exacerbations through Week 241,f
- Lung function improvement: Rapid FEV1 improvement at Week 2g and sustained through Week 521,11,h
- OCS reduction/elimination: 86% of patients reduced or eliminated their OCS dose at Week 2412,i
and Safety Data
ePlus ≥1 positive perennial-aeroallergen-specific IgE ≥0.35 kU/L at baseline.10
fWith DUPIXENT 300 mg Q2W + SOC (n=64) vs placebo + SOC (n=68) (0.20 vs 1.04; rate ratio: 0.19 [95% CI: 0.07, 0.56]) (DRI12544, EOS ≥300 cells/µL, secondary endpoint).1
g~72% of the total FEV1 improvement was seen at Week 2 with DUPIXENT 200 mg Q2W + SOC (n=264) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1,11
h470 mL sustained breathing relief was seen at Week 52 from baseline in pre-bronchodilator FEV1 with DUPIXENT 200 mg Q2W + SOC (n=264) vs 170 mL with placebo + SOC (n=148) (QUEST, EOS ≥300 cells/µL, secondary endpoint).1
iWith DUPIXENT 300 mg Q2W + SOC (n=103) vs 68% with placebo + SOC (n=107) (VENTURE, ITT population).12
EOS, eosinophils; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; ITT, intention-to-treat; OCS, oral corticosteroid; Q2W, once every 2 weeks, SOC, standard of care.
Mechanism of Action
(MOA)
Only DUPIXENT targets both IL-4 and IL-13 signaling, two of the key drivers of local and systemic type 2 inflammation1-5,a
aThe mechanism of dupilumab action has not been definitively established.1
Multiple Dosage and
Administration Options
Offer your patients 6 years and older flexible administration: at home or in office1
DUPIXENT MyWay is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.
99%
of OCS-dependent asthma patients who are commercially insured required no biomarker testing13
~99%
of commercially insured patients nationally are covered for DUPIXENT13,j,k
jThe Dedham Group Quality of Access
Tracking Report. March 2024.
kCoverage varies by type and plan.
Check formulary status in your area
See insurance coverage status, prior authorization, and step edit information for DUPIXENT.
Look up coverageContact a Field Representative
Connect with a DUPIXENT Field Representative to get answers to your
product-related questions.